CNS PHARMACEUTICALS, INC. (CNSP) News
Filter CNSP News Items
CNSP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CNSP News From Around the Web
Below are the latest news stories about CNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNSP as an investment opportunity.
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host ... |
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line TherapyCNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation ... |
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central ... |
CNS Pharmaceuticals Reports Third Quarter 2024 Financial ResultsPrimary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 Company strengthens cash position to extend runway to fund operations beyond data readout of Berubicin potentially pivotal GBM ... |
CNS Pharmaceuticals Announces Virtual Investor KOL Connect SegmentSegment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical ... |
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price RequirementHOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central ... |
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesHOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central ... |
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect SegmentSegment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust Access the segment here HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the ... |
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLCLive webcast fireside chat on Wednesday, October 16th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel ... |
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe ForumWebcast presentation on Wednesday, September 25th at 1:55 PM CEST HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel ... |